Goodbody Health Announces Rollout of Blood Testing Technology

Patterson-UTI Announces Strategic Investment in Geothermal Technology Company, Criterion Energy Partners

VANCOUVER, BC /ACCESSWIRE/March 8, 2022/ Goodbody Health Inc. (CSE: GDBY)(OTCQB: GDBYF) (Good body health“or the”Company“) is pleased to announce that following a pilot project using new technology to provide accessible and rapid blood test results (available in less than 10 minutes) in the local community, it has ordered a first installment of 100 Abbott blood test machines (the “Abbott Machinery“) for its existing network of clinics in the UK.

Using Abbott machines, Goodbody Health will administer blood tests for lipids (heart/cholesterol) and diabetes through the Company’s clinics. By identifying issues related to heart health and diabetes through its blood tests, the company hopes to help customers take control by adopting healthy lifestyle changes and furthering the company’s mission to help people to “know more, live better”.

According to Diabetes UK (, more than 4.9 million people have diabetes in the UK, of which 850,000 are currently living with type 2 diabetes and have not yet been diagnosed. If nothing changes, they predict 5.5 million people will have diabetes in the UK by 2023.

According to Public Health England (, one in four deaths in England, based on data of 2016, was caused by cardiovascular disease. Following this report, Public Health England estimates that ongoing healthcare costs in England will amount to £7.4 billion a year.

In January, the House Health and Social Care Committee said the NHS faced an “unquantifiable challenge” to cope with patients who have not been treated because many have health problems that have not yet been identified. Pointing to figures showing that 5.8 million patients are waiting for planned care as routine operations, he warned that the number “could double by 2025” and that the NHS faces an “unquantifiable challenge to tackle to a backlog of cases caused by the pandemic.”

With the rollout of the first phase of Abbott machines, Goodbody Health will be able to offer blood testing at more than 150 sites in the UK through its network of clinics and its partnership with Superdrug.

Geremy Thomas, Executive Chairman, said: “I am pleased that we are able to use technology, in the local community, to offer customers the opportunity to undertake a rapid health check of their blood, the results of which can enable them to make decisions to improve their life.”

The Directors of the Company accept responsibility for the content of this announcement.

On behalf of the Board of Directors,

Marc Howells
Chief Executive Officer
Goodbody Health Inc.
+44 (0) 20 7971 1255
[email protected]

Anne Tew
Financial director
Goodbody Health Inc.
+44 (0) 20 7971 1255
[email protected]

Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities laws and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act. . of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or of the current situation, but rather represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and beyond the control of Goodbody Health. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “anticipates”, “expects” or “does not expect”, “is expected”, ” budget”, “planned”, “estimates”, “plans”, “intends”, “anticipates” or “does not anticipate”, or “believes” “plans” or variations of these words and expressions or may contain statements that certain actions, events or results “may”, “could”, “will”, “could” or “will be taken”, “will continue”, “will occur”, “will be achieved” or “soon” Forward-looking information and forward-looking statements contained herein include, but are not limited to: blood tests provided by the Company; the Company’s plans for Abbott machines; identification of heart health issues and to diabetes; the incidence of diabetes; the expected healthcare costs and the ability of test results to enable patients to people to make decisions to improve their lives.

Although Goodbody Health believes that the assumptions and factors used in the preparation and expectations contained in the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurances or warranties can be made. that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. This is due to the interrelationship between future services offered free of charge by the NHS, comparative competing services and other future health factors, as well as the dependence on the growth of the network of partner clinics and their ability to deliver the services as planned.

Goodbody Health does not undertake to update any forward-looking information and/or forward-looking statements contained or referenced herein, except in accordance with applicable securities laws.

THE SOURCE: Goodbody Health Inc.

See the source version on